Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue
+14.5%
EPS
−43.6%
Free cash flow
+28.9%
Total debt
+142.7%

Quarter to September 2026, against a year earlier

110.32 3.28 −2.89%
Market cap
$196.6B
P/E
42.3×
Fwd P/E
35.1×
Dividend yield
2.22%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100

Abbott Laboratories 8-K filed Jan 22, 2025

Period ended Jan 22, 2025 · Filed · accepted 7:13 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release